Below are the most recent publications written about "Half-Life" by people in Profiles.
-
Wu QC, Lee J, Swaminathan A, Winward A, Hwang Y, Socolovsky M, Way JC, Klein AM. Linker minimization and characterization of Fc-fused interleukin-17A for increased in vivo half-life. Protein Eng Des Sel. 2025 Jan 10; 38.
-
Foss S, Sakya SA, Aguinagalde L, Lustig M, Shaughnessy J, Cruz AR, Scheepmaker L, Mathiesen L, Ruso-Julve F, Anthi AK, Gj?lberg TT, Mester S, Bern M, Evers M, Bratlie DB, Michaelsen TE, Schlothauer T, Sok D, Bhattacharya J, Leusen J, Valerius T, Ram S, Rooijakkers SHM, Sandlie I, Andersen JT. Human IgG Fc-engineering for enhanced plasma half-life, mucosal distribution and killing of cancer cells and bacteria. Nat Commun. 2024 Mar 07; 15(1):2007.
-
Mo Y, Shcherbakova N, Inman KL, Li WK, Kovalenko K, Rosenberg J, Orsini J, Truong J. Evaluation of Individualized Cefepime Dosing Strategy Using Population Pharmacokinetics. J Clin Pharmacol. 2022 03; 62(3):359-365.
-
Belaghzal H, Borrman T, Stephens AD, Lafontaine DL, Venev SV, Weng Z, Marko JF, Dekker J. Liquid chromatin Hi-C characterizes compartment-dependent chromatin interaction dynamics. Nat Genet. 2021 03; 53(3):367-378.
-
Liu Y, Liang X, Zou Y, Peng Y, McClements DJ, Hu K. Resveratrol-loaded biopolymer core-shell nanoparticles: bioavailability and anti-inflammatory effects. Food Funct. 2020 May 01; 11(5):4014-4025.
-
Mauger DM, Cabral BJ, Presnyak V, Su SV, Reid DW, Goodman B, Link K, Khatwani N, Reynders J, Moore MJ, McFadyen IJ. mRNA structure regulates protein expression through changes in functional half-life. Proc Natl Acad Sci U S A. 2019 11 26; 116(48):24075-24083.
-
Johnson ER, Taylor AR, Boothe DM, Gray-Edwards HL, Winter RL, Martin DR. Pharmacokinetics of a commercially available product and a compounded formulation of extended-release levetiracetam after oral administration of a single dose in cats. Am J Vet Res. 2019 Oct; 80(10):950-956.
-
Cordeiro N, Gupta SS, Lindsay D, Seneviratne C, Kulbak G, Kupfer Y. Midodrine: Associated Bradycardia. Am J Ther. 2019 Sep/Oct; 26(5):e655-e656.
-
Santoni M, Massari F, Piva F, Carrozza F, Di Nunno V, Cimadamore A, Martignetti A, Montironi R, Battelli N. Tivozanib for the treatment of renal cell carcinoma. Expert Opin Pharmacother. 2018 Jun; 19(9):1021-1025.
-
Ganz DE, Sexton-Stallone B, Brackett EL, Forbes NS. Tissue transport affects how treatment scheduling increases the efficacy of chemotherapeutic drugs. J Theor Biol. 2018 02 07; 438:21-33.